0800 GMT - AstraZeneca's decision to not upgrade its full-year guidance was a little disappointing given its strong performance, Hargreaves Lansdown's Derren Nathan writes. Its reiterated guidance now looks relatively easy to achieve, Nathan adds. The Anglo-Swedish pharmaceutical giant's share price has been dragged down by fears of U.S. tariffs and policy on drug pricing but the concerns appear to have been overplayed, he adds. Shares trade up 0.5% at 10,840 pence. (adam.whittaker@wsj.com)
(END) Dow Jones Newswires
July 29, 2025 04:00 ET (08:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.